Diagnosis, prognosis and monitoring of cardiovascular disease, by determining at least one of soluble CD40 ligand, pregnancy-associated plasma protein-A or placental growth factor

摘要

Analysis of samples associated with acute cardiovascular disease by determining the concentration of at least one of the markers soluble CD40 ligand (sCD40L); PAPP-A (pregnancy-associated plasma protein-A) and placental growth factor (PlGF), and comparing the result with reference values or results from reference samples. Analysis of samples associated with acute cardiovascular disease by determining the concentration of at least one of the markers soluble CD40 ligand (sCD40L); PAPP-A (pregnancy-associated plasma protein-A) and placental growth factor (PlGF), and comparing the result with reference values or results from reference samples. Optionally at least one of the additional markers troponin T (TnT), MPO (not defined), NT-pro-BNP (brain natriuretic peptide), VEGF (vascular endothelial growth factor), BNP or additional inflammation markers are also determined and compared. An independent claim is also included for a diagnostic kit comprising reagents for performing the new method, optionally also other components and/or auxiliaries.